Product line
Product Description
Drostanolone propionate, an androgen and anabolic steroid, is employed for palliating androgen-responsive recurrent breast cancer in postmenopausal women ranging from more than one year to less than five years.
It functions by inhibiting prolactin or estrogen receptors in the breasts, correlating with its antitumor effect. Additionally, it interacts with the androgen receptor, initiating genetic changes that augment protein synthesis (anabolism) and curtail amino acid degradation (catabolism).
Contraindications
- Allergy or hypersensitivity to drostanolone propionate or any constituent of this drug.
- Breast cancer in males.
- Known or suspected prostate cancer.
- Confirmed or planned pregnancy.
- Serious cardiac ailments.
- Chronic hepatic or renal diseases.
Dosage and Side Effects
This drug is exclusively administered intramuscularly, with the recommended dose at 1.4 mg/kg of body weight three times weekly.
Similar to all medications, Drostanolone propionate may induce side effects. The drug does not exhibit estrogenic effects.
The following side effects (frequency data unavailable) were observed during treatment:
In Women: Irreversible signs of virilization (refer to Precautions).
In Men: Baldness, heightened body hair growth, acne, suppression of testosterone production causing reduced muscle volume and strength, decreased libido, erectile dysfunction, and increased irritability.
In Both Sexes: Hypercalcemia, elevated "bad" cholesterol levels, and notable reduction in "good" cholesterol levels.